Carillon Tower Advisers’s Abiomed Inc ABMD Stock Holding History

Carillon Tower Advisers’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$19.5M	Sell	60,160 -3,040	-5%	-$841K	0.12%	244
2020 Q3	$17.5M	Sell	63,200 -27,027	-30%	-$7.79M	0.23%	161
2020 Q2	$21.8M	Buy	+90,227	New	+$18.1M	0.17%	183
2019 Q4	–	Sell	-113,675	Closed	-$20.2M	–	490
2019 Q3	$20.2M	Sell	113,675 -194,817	-63%	-$42.1M	0.14%	246
2019 Q2	$80.4M	Buy	308,492 +91,218	+42%	+$24.2M	0.55%	41
2019 Q1	$62M	Buy	217,274 +41,589	+24%	+$13.8M	0.44%	66
2018 Q4	$57.1M	Sell	175,685 -132,319	-43%	-$46M	0.48%	52
2018 Q3	$135M	Sell	308,004 -92,344	-23%	-$36.4M	0.96%	3
2018 Q2	$164M	Buy	400,348 +174,198	+77%	+$63.1M	1.29%	2
2018 Q1	$110M	Buy	226,150 +68,574	+44%	+$17.4M	0.86%	17
2017 Q4	$29.5M	Buy	+157,576	New	+$29.4M	0.31%	116

Other funds holding ABMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Carillon Tower Advisers's ABMD Position: Q4 2020 in Review

Carillon Tower Advisers reduced its Abiomed Inc (ABMD) stake by 4.8% in Q4 2020, selling an estimated $841K and leaving 60,160 shares worth $19.5M. The position accounts for 0.12% of the portfolio, ranked #244.

Carillon Tower Advisers first reported a position in ABMD in Q4 2017 and has held it in 11 quarters since. The position peaked at $164M in Q2 2018. 499 funds tracked by Wall St. Rank hold ABMD as of Q4 2020.

Carillon Tower Advisers held 60,160 shares of Abiomed Inc worth $19.5M as of Q4 2020.
Carillon Tower Advisers sold 3,040 Abiomed Inc shares in Q4 2020, an estimated $841K.
Abiomed Inc made up 0.12% of Carillon Tower Advisers's portfolio in Q4 2020, its #244 holding.
Carillon Tower Advisers first reported a position in Abiomed Inc in Q4 2017 and has held it in 11 quarters since.
Carillon Tower Advisers's Abiomed Inc position peaked at $164M in Q2 2018.
499 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2020.

Based on Carillon Tower Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.